Ribupatide oral tablet by Kailera Therapeutics: status and timeline

Milestones

Next · Oral formulation IND-enabling studies ongoing

Oral formulation IND-enabling studies ongoingTarget 2026Current milestone.
Phase 3 obesity trial initiation (planned)Target 2027Not yet reached.

Upcoming

2026Oral formulation IND-enabling studies ongoing (next)
2027Phase 3 obesity trial initiation (planned)

Current obstacles

Oral bioavailability of dual agonistsSmall molecules must survive acid and be absorbed while maintaining potency at both receptors.

Physics limits

Peptide mimicry complexityPeptides bind receptors with high specificity through 3D structure; designing a small molecule with equivalent binding and activation of two receptors is significantly harder.

How it works

2 parts

Small-molecule design

Non-peptide dual agonist

Small-molecule chemistry enables oral absorption while maintaining dual GLP-1/GIP activity.

Once-daily dosing

Improved convenience

Daily pill offers simplicity versus weekly injection for patients preferring oral medications.

About Kailera Therapeutics

The team behind Ribupatide oral tablet

Kailera Therapeutics

GLP-1/GIP obesity, ribupatide injectable

Kailera develops GLP-1/GIP receptor dual agonists for obesity and metabolic disorders. Founded in October 2024 with $400M Series A, the company raised over $1B total and completed its IPO in April 2026 to fund Phase 3 trials and manufacturing scale-up.

Ribupatide Phase 2: 17.7% mean weight loss vs placebo at 48 weeks; 88% achieved ≥5% weight loss.
Total raised: $400M Series A (2024) + $600M Series B (2025) + $500M IPO (April 2026).
Phase 3 KaiNETIC program enrolling 4,700+ patients; oral form in development for H1 2027.

kailera.com (opens kailera.com)Company profile →

Founded: 20242 yrs
Headquarters: United States
Status: Public
Valuation: $500Mdeal valueApr 2026
Raised: $1B2 rounds
Last round: IPO · $500MApr 2026
Works in: BiotechObesity & metabolism
Coverage: 2 programs · 4 updateslatest 1 Apr 2026checked 11 Oct
Lead investors: Bain Capital Private EquityAtlas VentureBain Capital Life SciencesRTW Investments
Partners: Jiangsu Hengrui Pharmaceuticals (opens hengrui.com.cn)
Investors: Bain Capital Private Equity (opens baincapital.com)
People: Ron Renaud (opens linkedin.com)President and Chief Executive OfficerScott WassermanChief Medical OfficerPaul BurgessChief Operating Officer and Chief Business Officer